Purple Biotech to Change ADS Ratio
Ticker: PPBT · Form: 6-K · Filed: Sep 11, 2024 · CIK: 1614744
Sentiment: neutral
Topics: ADS-ratio-change, corporate-action, pharmaceutical
TL;DR
Purple Biotech changing its ADS ratio - could shake up trading.
AI Summary
Purple Biotech Ltd. announced on September 11, 2024, its intention to change the ratio of its American Depositary Shares (ADSs) to its ordinary shares. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel, and operates in the pharmaceutical preparations sector.
Why It Matters
Changes in ADS ratios can impact the trading price and liquidity of the ADSs, potentially affecting investor accessibility and market perception.
Risk Assessment
Risk Level: medium — Changes to ADS ratios can introduce volatility and uncertainty for investors, impacting share price and liquidity.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- Kitov Pharma Ltd. (company) — Former company name
- September 11, 2024 (date) — Filing date
FAQ
What is the primary purpose of this 6-K filing?
The filing is to report that Purple Biotech Ltd. plans to change the ratio of its American Depositary Shares (ADSs) to its ordinary shares.
What was Purple Biotech Ltd. previously known as?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
When did the company last change its name?
The company last changed its name from Kitov Pharma Ltd. on January 25, 2018.
Where is Purple Biotech Ltd. located?
The company's principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot, Israel.
Under which form does Purple Biotech Ltd. typically file annual reports?
Purple Biotech Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 1,621 words · 6 min read · ~5 pages · Grade level 20 · Accepted 2024-09-11 16:15:29
Key Financial Figures
- $1.00 m — e Company to regain compliance with the $1.00 minimum bid price requirement for continu
Filing Documents
- ea0214212-6k_purple.htm (6-K) — 27KB
- 0001213900-24-077719.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. September 11, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 3